Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Jul;74(13):6186-92.
doi: 10.1128/jvi.74.13.6186-6192.2000.

Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41

Affiliations

Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41

M K Gorny et al. J Virol. 2000 Jul.

Abstract

Human immunodeficiency virus type 1 (HIV-1) entry into target cells appears to be triggered when two heptad repeat regions in the ectodomain of gp41 associate, converting the prefusogenic form of gp41 to a fusogenic form. Peptides from these two heptad repeat regions, designated N51 and C43, form a coiled coil consisting of an alpha-helical trimer of heterodimers which approximates the core of the fusogenic form of gp41. To understand the antigenic structures of gp41 in these two configurations, and to examine the specificity of anti-gp41 antibodies produced by HIV-1-infected individuals, human anti-gp41 monoclonal antibodies (MAbs) were tested for their reactivity against N51, C43, and the complex formed by these peptides. Of 11 MAbs, 7 reacted with the complex but with neither of the parent peptides. These MAbs reacted optimally with the N51-C43 complex prepared at a 1:1 ratio and appeared to recognize the fusogenic form of gp41 in which the two heptad repeat regions are associated to form the coiled coil. The existence of antibodies from HIV-infected humans that exclusively recognize the N51-C43 complex constitutes the first proof that the coiled-coil conformation of gp41 exists in vivo and is immunogenic. Two of the 11 MAbs were specific for the hydrophilic loop region of gp41 and failed to react with either peptide alone or with the peptide complex, while the remaining 2 MAbs reacted with peptide C43. One of these two latter MAbs, 98-6, also reacted well with the equimolar N51-C43 complex, while reactivity with C43 by the other MAb, 2F5, was inhibited by even small amounts of N51, suggesting that the interaction of these peptides occludes or disrupts the epitope recognized by MAb 2F5. MAbs 98-6 and 2F5 are also unusual among the MAbs tested in their ability to neutralize multiple primary HIV isolates, although 2F5 displays more broad and potent activity. The data suggest that anti-gp41 neutralizing activity is associated with specificity for a region in C43 which participates in complex formation with N51.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Binding of anti-gp41 MAbs to peptide C43 (A) or to the N51-C43 complex formed in solution at a 1:1 ratio (B). The peptide and the complex were each applied to ELISA plates at 1.0 μg/ml. The anti-gp41 MAbs used are identified on the right; MAb 670-D is specific for the C5 region of gp120 and was used as a negative control. Results are from one of three experiments giving essentially identical results.
FIG. 2
FIG. 2
Binding of gp41 MAbs to N51-C43 complexes formed at different ratios. (A and C) Peptide N51 was applied to plates at 1.0 μg/ml and then incubated with peptide C43 at concentrations of between 0.001 and 1.0 μg/ml, resulting in complexes where the ratio of N51 to C43 ranged from 1,000:1 to 1:1. (B and D) Peptide C43 was applied to plates at 1.0 μg/ml and then incubated with peptide N51 at concentrations of between 1.0 and 0.001 μg/ml, resulting in complexes where the ratio ranged from 1:1 to 0.001:1. Each MAb (designated by symbols shown on the right) was tested for binding at a concentration of 1.0 μg/ml.
FIG. 3
FIG. 3
Binding of biotinylated anti-gp41 MAb 126-6 (126-6*) to N51-C43 complexes in solution. MAb 126-6* was incubated with N51 and C43 in solution, and the N51–C43–126-6* product was captured by MAb 50-69 bound to an ELISA plate (□ and ○). Neither N51 alone (formula image) nor C43 alone (▴) bound 126-6*. When unlabeled 126-6 was added to the incubation mixture of N51, C43, and 126-6*, the unlabeled MAb inhibited the binding of 126-6*, showing the specificity of the interaction (□). An irrelevant unlabeled MAb, 1418, to parvovirus B19, did not interfere with the interaction of N51, C43, and 126-6* (○).

Similar articles

Cited by

References

    1. Barin F, McLane M F, Allan J S, Lee T H, Groopman J E, Essex M. Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science. 1985;228:1094–1098. - PubMed
    1. Binley J M, Ditzel H J, Barbas III C F, Sullivan N, Sodroski J, Parren P W H I, Burton D R. Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. AIDS Res Hum Retroviruses. 1996;12:911–924. - PubMed
    1. Blacklow S C, Lu M, Kim P S. A trimeric subdomain of the simian immunodeficiency virus envelope glycoprotein. Biochemistry. 1995;34:14955–14962. - PubMed
    1. Cantin R, Fortin J-F, Lamontagne G, Tremblay M. The acquisition of host-derived major histocompatibility complex class II glycoproteins by human immunodeficiency virus type 1 accelerates the process of virus entry and infection in human T lymphoid cells. Blood. 1997;90:1091–1100. - PubMed
    1. Chambers P, Prignle C R, Easton A J. Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. J Gen Virol. 1990;71:3075–3080. - PubMed

Publication types

MeSH terms

LinkOut - more resources